COVID-19 and immunomodulator/immunosuppressant use in dermatology - 14/04/20
Funding sources: None. |
|
Conflicts of interest: Dr Shi is a stock shareholder of Learn Health and has served as an advisory board member, investigator, and/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Eli Lilly, Novartis, Sun Pharma, LEO Pharma, Pfizer, Menlo Therapeutics, Burt’s Bees, GpSkin, Altus Labs, and Skin Actives Scientific. There were no incentives or transactions, financial or otherwise, relevant to this manuscript. Kyla N. Price and Drs Frew and Hsiao have no conflicts of interest to declare. |
|
IRB approval status: Not applicable. |
|
Accepted for publication March 20, 2020. |
|
Reprints not available from the authors. |
Vol 82 - N° 5
P. e173-e175 - mai 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.